Y. Morita et al., THE ROLE OF COMPLEMENT IN THE PATHOGENESIS OF TUBULOINTERSTITIAL LESIONS IN RAT MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS, Journal of the American Society of Nephrology, 8(9), 1997, pp. 1363-1372
Persistent proteinuria and tubulointerstitial lesions are important si
gns of progressive renal disease. The purpose of this study was to ass
ess the role of complement in the development of tubulointerstitial le
sions in rats with proteinuria due to primary glomerulonephritis. Mesa
ngial proliferative glomerulonephritis was induced in mononephrectomiz
ed rats by intravenous injection of monoclonal antibody (mAb) 1-22-3 (
Clin Exp Immunol 102: 181-185, 1995). As early as 24 h after the injec
tion, proteinuria became evident, persisted throughout the observation
period, and was associated with mesangial cell proliferation and tubu
lointerstitial lesions when examined at 7 and 14 d after mAb administr
ation. Deposition of rat C3 and C5b-9 was observed at the luminal surf
ace of proximal tubules and in cellular debris present in the tubular
lumen (group I). Rats injected with mAb 1-22-3 and depleted of complem
ent by injections of cobra venom factor starting at day 3 developed gl
omerulonephritis and proteinuria comparable to rats of group I, but co
mplement deposition in the tubules and the tubulointerstitial lesions
were markedly reduced (group II). Rats in group IU were injected with
mAb and, from day 3, with soluble complement receptor type 1, which be
came detectable at the luminal surface of proximal tubules and in the
urine. Deposition of C5b-9 in tubular cells was not detectable, and th
e severity of tubulointerstitial lesions was reduced compared with rat
s in group I. These results indicate that, in this model of primary me
sangial proliferative glomerulonephritis with proteinuria, the develop
ment of tubulointerstitial lesions is associated with activation of se
rum complement at the level of tubular brush border, and tubulointerst
itial lesions can be reduced by inhibition of complement activity.